Skip to content
Glucagon, Baqsimi(glucagon)
Baqsimi, Glucagen, Gvoke, Ogluo (glucagon) is a protein pharmaceutical. Glucagon was first approved as Glucagon on 1982-01-01. It is used to treat anaphylaxis, bradycardia, cardiogenic shock, hypoglycemia, and hypotension in the USA. It has been approved in Europe to treat diabetes mellitus. The pharmaceutical is active against glucagon receptor. In addition, it is known to target glucagon-like peptide 2 receptor and glucagon-like peptide 1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Baqsimi, Glucagen, Gvoke (generic drugs available since 2020-12-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glucagon
Tradename
Company
Number
Date
Products
BAQSIMIEli LillyN-210134 RX2019-07-24
1 products, RLD, RS
GLUCAGONEli LillyN-020928 RX1998-09-11
1 products, RLD, RS
GVOKE KITXeris Biopharma HoldingsN-212097 RX2021-08-20
1 products, RLD, RS
GVOKE PFSXeris Biopharma HoldingsN-212097 RX2019-09-10
1 products, RLD, RS
GVOKE HYPOPENXeris Biopharma HoldingsN-212097 RX2019-09-10
2 products, RLD, RS
Show 1 discontinued
Glucagon hydrochloride
Tradename
Company
Number
Date
Products
GLUCAGONFresenius KabiN-201849 RX2015-05-08
1 products, RLD, RS
GLUCAGENNovo NordiskN-020918 RX1998-06-22
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
baqsimiNew Drug Application2020-10-27
glucag0nNew Drug Application2022-12-09
gvoke hypopen gvoke pfsNew Drug Application2021-03-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
anaphylaxis—D000707T78.2
bradycardiaHP_0001662D001919R00.1
cardiogenic shock—D012770R57.0
hypoglycemiaHP_0001943D007003E16.2
hypotensionEFO_0005251D007022I95
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Glucagon, Baqsimi, Eli Lilly And Co
107656022039-09-23DP
108941332038-01-03DP
102134872036-02-16DPU-2604
Glucagon, Gvoke Hypopen, Xeris
96493642036-04-22DPU-2742
115902052036-04-22DPU-2742
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H04: Pancreatic hormones
— H04A: Glycogenolytic hormones
— H04AA: Glycogenolytic hormones
— H04AA01: Glucagon
HCPCS
Code
Description
J1610
Injection, glucagon hydrochloride, per 1 mg
Clinical
Clinical Trials
160 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E1017161141762
Type 2 diabetes mellitusD003924EFO_0001360E11101—12334
HypoglycemiaD007003HP_0001943E16.281181533
ObesityD009765EFO_0001073E66.95221311
Drug overdoseD062787———1—1
Colonic neoplasmsD003110C18———1—1
Liver diseasesD008107EFO_0001421K70-K77———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2—1—36
Diabetes mellitusD003920EFO_0000400E08-E13——4—26
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8121——46
Congenital hyperinsulinismD044903—2———2
Short bowel syndromeD01277811———1
Critical illnessD016638—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333EFO_00026142————2
Insulin secretionD0000787901————1
Common coldD003139EFO_0007214J001————1
Heart failureD006333EFO_0003144I501————1
Prediabetic stateD011236EFO_1001121R73.031————1
HyperinsulinismD006946HP_0000842E16.11————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I98————22
Metabolic syndromeD024821EFO_0000195E88.81————22
Glucose metabolism disordersD044882————22
Liver cirrhosisD008103EFO_0001422K74.0————22
StrokeD020521EFO_0000712I63.9————22
Myocardial infarctionD009203EFO_0000612I21————22
Chronic renal insufficiencyD051436N18————22
Diabetic nephropathiesD003928EFO_0000401————11
Diabetes insipidusD003919E23.2————11
Alcoholic fatty liverD005235K70.0————11
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGLUCAGON
INNglucagon
Description
GLUCAGON
Classification
Protein
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O
Identifiers
PDB—
CAS-ID9007-92-5
RxCUI4832
ChEMBL IDCHEMBL266481
ChEBI ID5391
PubChem CID16186314
DrugBankDB00040
UNII ID76LA80IG2G (ChemIDplus, GSRS)
Target
Agency Approved
GCGR
GCGR
Organism
Homo sapiens
Gene name
GCGR
Gene synonyms
NCBI Gene ID
2642
Protein name
glucagon receptor
Protein synonyms
Uniprot ID
Q2M3M5
Mouse ortholog
Gcgr (14527)
glucagon receptor (Q8K0B5)
Alternate
GLP2R
GLP2R
GLP1R
GLP1R
Organism
Homo sapiens
Gene name
GLP2R
Gene synonyms
NCBI Gene ID
9340
Protein name
glucagon-like peptide 2 receptor
Protein synonyms
epididymis secretory sperm binding protein, GLP-2 receptor
Uniprot ID
Q4VAT3
Mouse ortholog
Glp2r (93896)
glucagon-like peptide 2 receptor (Q5SU65)
Variants
Clinical Variant
No data
Financial
Gvoke - Xeris Biopharma Holdings
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Glucagon - Amphastar Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 79,426 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,844 adverse events reported
View more details